Ascent Group LLC Purchases 1,056 Shares of Medpace Holdings, Inc. $MEDP

Ascent Group LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 6.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,387 shares of the company’s stock after purchasing an additional 1,056 shares during the quarter. Ascent Group LLC owned approximately 0.07% of Medpace worth $10,327,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. AQR Capital Management LLC grew its holdings in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after buying an additional 404,226 shares in the last quarter. Wasatch Advisors LP boosted its position in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the period. Baillie Gifford & Co. grew its stake in Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after acquiring an additional 62,503 shares in the last quarter. Invesco Ltd. grew its stake in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after acquiring an additional 85,517 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Medpace by 205.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after acquiring an additional 211,411 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP stock opened at $498.34 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The firm has a market cap of $14.14 billion, a P/E ratio of 32.57, a P/E/G ratio of 2.39 and a beta of 1.39. The business’s 50 day moving average price is $482.05 and its 200-day moving average price is $537.23.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. Medpace’s quarterly revenue was up 32.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Truist Financial lowered their price target on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Leerink Partners cut their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada began coverage on shares of Medpace in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.